Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Recommend:
0
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
Recommend :
0
React to this article
Latest news
Date Title
<1m ago H & R BLOCK : Tax Examiner Discusses Online 2014, 2015 Tax Refund Calculator from H&R Block
4m ago OCWEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL : Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ocwen Financial Corp. -- OCN
5m ago DEXUS PROPERTY : celebrates Excellence in Agency Awards
7m ago DDS : Orange Coast Magazine and Five Star Professional Name Newport Beach Dentist George Maddox Top Cosmetic Dentist in Southern California for Fourth Consecutive Year
8m ago ROOSTER ENERGY : Announces Second Quarter 2014 Financial and Operating Results and Provides Update on Debt Financing
8m ago NEUSTAR : SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NeuStar, Inc.
9m ago VEEVA SYSTEMS : to Participate in Upcoming Investor Conference
10m ago MESOBLAST : Company Secretary Appointment/Resignation
11m ago SANDFIRE RESOURCES NL : Early Warning Report
14m ago GBP/USD Needs Greater BoE Dissent to Breakout of Bearish Trend
Latest news
Advertisement
Hot News 
UNITED THERAPEUTICS : District Court Decision Received In Remodulin Patent Case
FORBIDDEN TECHNOLOGIES : Integrates Timecode Buddy into Forscene Platform via MovieSlate iOS App
THERAMETRICS : SIX: TMX) today announces its financial results for the first half year ended June 30, 2014
ADL PARTNER : 08/28/2014 - ADLPartner: EARNINGS GROWTH FOR THE FIRST HALF OF 2014
BWIN PARTY DIGITAL ENTERTAINMENT : 2014 Half Year Dividend
Most Read News
2h ago BANK OF NEW YORK MELLON : Argentina to appeal U.S. judge's order on bond payment
4h ago Intel hires senior Qualcomm exec to boost mobile business
4h ago SONORO ENERGY : Files Second Quarter 2014 Financial Statements
4h ago COLUMBUS GOLD : Satisfies Obligation Respecting Paul Isnard
4h ago DIGITAL SHELF SPACE : Announces Unaudited Financial Results for the Six Months Ending June 30, 2014 and Stock Option Grants
Most recommended articles
5h ago S&P 500 edges up to set new record; best month since Feb
14m ago GBP/USD Needs Greater BoE Dissent to Breakout of Bearish Trend
44m ago Gold Posts Monthly Gain But Prices Vulnerable Ahead of NFPs- $1271 Key
48m ago Canadian Dollar Faces Conflicting Cues from BOC, Key US Data
59m ago U.S. coal stocks could gain on Russia tension
Dynamic quotes  
ON
| OFF